UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Budget Impact of Metastatic Castrate-Resistant Prostate Cancer (CRPC) to German Payers

Value in health, 2013-11, Vol.16 (7), p.A398-A398

2013

Volltextzugriff (PDF)

Use of Oritavancin for the Treatment of Skin and soft Tissue Infections: A Uk Hospital Budget Impact Analysis

Value in health, 2015-05, Vol.18 (3), p.A233-A233

2015

Volltextzugriff (PDF)

PIN9 A German Hospital Budget Impact Model Comparing Antibiotic Therapies in Complicated Skin and Skin Structure Infections and Bacteremia

Value in health, 2012-06, Vol.15 (4), p.A238-A238

2012

Volltextzugriff (PDF)

PSU15 Impact of Complications in Solid Organ Transplants on Hospital Charges and Length of Stay

Value in health, 2012-06, Vol.15 (4), p.A76-A76

2012

Volltextzugriff (PDF)

EE539 Estimating the Lifetime Burden of Illness in Patients with Bronchiolitis Obliterans Syndrome (BOS)

Value in health, 2023-06, Vol.26 (6), p.S157-S158

2023

Volltextzugriff (PDF)

EE285 Evaluating the Face Validity of Health State Utility Values (HSUVS) for Metachromatic Leukodystrophy (MLD)

Value in health, 2023-06, Vol.26 (6), p.S111-S111

2023

Volltextzugriff (PDF)

PGI9 Impact of Dysphagia on U.S. Hospital Charges in Patients with Comorbid Conditions

Value in health, 2011, Vol.14 (7), p.A393-A393

2011

Volltextzugriff (PDF)

PGI7 Impact of Complications from Dysphagia on Hospital Charges in the United States

Value in health, 2011, Vol.14 (7), p.A392-A393

2011

Volltextzugriff (PDF)

Incorporating Stakeholder Input into Budget Impact Models to Compare Stem Cell Mobilization Strategies

Value in health, 2013-11, Vol.16 (7), p.A399-A399

2013

Volltextzugriff (PDF)

EE393 The Cost-Effectiveness of Atidarsagene Autotemcel (Arsa-Cel) for the Treatment of Metachromatic Leukodystrophy (MLD) in the US

Value in health, 2023-12, Vol.26 (12), p.S126

2023

Volltextzugriff (PDF)

EE547 The Societal Costs of Metachromatic Leukodystrophy (MLD) in the United States

Value in health, 2023-12, Vol.26 (12), p.S157-S158

2023

Volltextzugriff (PDF)

EE125 Cost Consequences of Using Clevidipine in Acute Hypertension from the Perspective of a US Hospital

Value in health, 2023-12, Vol.26 (12), p.S74

2023

Volltextzugriff (PDF)

EE734 Cost Consequences of Using Clevidipine in Cardiac Surgery from the Perspective of a US Hospital

Value in health, 2023-12, Vol.26 (12), p.S196

2023

Volltextzugriff (PDF)

EE579 Cost Consequences of Using Clevidipine in Neurological Emergencies from the Perspective of a US Hospital

Value in health, 2023-12, Vol.26 (12), p.S164

2023

Volltextzugriff (PDF)

EE303 Cost-Utility Analysis of Roflumilast Cream for Plaque Psoriasis, Including Intertriginous, From the Canadian Societal Perspective

Value in health, 2023-12, Vol.26 (12), p.S109

2023

Volltextzugriff (PDF)

EE408 Direct Cost Analysis Associated with the Management of Patients with Metachromatic Leukodystrophy (MLD) across Nine European Countries

Value in health, 2023-06, Vol.26 (6), p.S134-S134

2023

Volltextzugriff (PDF)

EE658 Cost-Consequence of Cladribine Tablets for the Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis (RRMS) in the UK

Value in health, 2023-12, Vol.26 (12), p.S180

2023

Volltextzugriff (PDF)

PMS57 Understanding the Impact of XLMTM on Parents and Caregivers in the US: An Analysis of Survey Results

Value in health, 2020-12, Vol.23, p.S601-S601

2020

Volltextzugriff (PDF)

PCN38 ECONOMIC ANALYSIS OF COLORECTAL CANCER SCREENING FROM MULTIPLE STAKEHOLDER PERSPECTIVES: KEY COMPONENTS TO IMPROVE PRACTICAL APPLICATIONS IN THE US

Value in health, 2019-05, Vol.22, p.S62-S63

2019

Volltextzugriff (PDF)

PRO10 USE OF SINGLE DOSE GENE-REPLACEMENT THERAPY FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY TYPE 1: A UNITED STATES PAYER BUDGET IMPACT ANALYSIS

Value in health, 2019-05, Vol.22, p.S336-S337

2019

Volltextzugriff (PDF)

ND2 COST-UTILITY ANALYSIS OF SINGLE DOSE GENE-REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY TYPE 1 COMPARED TO CHRONIC NUSINERSEN TREATMENT

Value in health, 2019-05, Vol.22, p.S42-S43

2019

Volltextzugriff (PDF)

PBI10 TYPE I SPINAL MUSCULAR ATROPHY PATIENTS TREATED WITH AVXS-101 HAVE LOWER USE OF VENTILATORY SUPPORT, HOSPITALIZATION, AND ASSOCIATED COSTS COMPARED TO THOSE TREATED WITH NUSINERSEN

Value in health, 2019-05, Vol.22, p.S48-S48

2019

Volltextzugriff (PDF)

PCN38 - Budget Impact of Metastatic Castrate-Resistant Prostate Cancer (CRPC) to German Payers

Value in health, 2013-11, Vol.16 (7), p.A398-A398

2013

Volltextzugriff (PDF)

PIN32 - Use of Oritavancin for the Treatment of Skin and soft Tissue Infections: A Uk Hospital Budget Impact Analysis

Value in health, 2015-05, Vol.18 (3), p.A233-A233

2015

Volltextzugriff (PDF)

PSS10 - A Us Hospital Economic Impact Model for Oritavancin In Absssi Patients With Risk of Mrsa Infections

Value in health, 2014-11, Vol.17 (7), p.A605-A605

2014

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(55)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(13)
Humans
(8)
Internal Medicine
(8)
Adult
(6)
Female
(6)
Biological And Medical Sciences
(5)
Male
(5)
Fundamental And Applied Biological Sciences. Psychology
(4)
Physical Sciences
(4)
Biotechnology
(3)
Middle Aged
(3)
Oncology
(3)
Radiology, Nuclear Medicine & Medical Imaging
(3)
Technology
(3)
Aged
(2)
Analytical Chemistry
(2)
Chemistry
(2)
Energy Levels
(2)
Gene Expression
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Budget Impact of Metastatic Castrate-Resistant Prostate Cancer (CRPC) to German Payers

Use of Oritavancin for the Treatment of Skin and soft Tissue Infections: A Uk Hospital Budget Impact Analysis

PIN9 A German Hospital Budget Impact Model Comparing Antibiotic Therapies in Complicated Skin and Skin Structure Infections and Bacteremia

PSU15 Impact of Complications in Solid Organ Transplants on Hospital Charges and Length of Stay

EE539 Estimating the Lifetime Burden of Illness in Patients with Bronchiolitis Obliterans Syndrome (BOS)

EE285 Evaluating the Face Validity of Health State Utility Values (HSUVS) for Metachromatic Leukodystrophy (MLD)

PGI9 Impact of Dysphagia on U.S. Hospital Charges in Patients with Comorbid Conditions

PGI7 Impact of Complications from Dysphagia on Hospital Charges in the United States

Incorporating Stakeholder Input into Budget Impact Models to Compare Stem Cell Mobilization Strategies

EE393 The Cost-Effectiveness of Atidarsagene Autotemcel (Arsa-Cel) for the Treatment of Metachromatic Leukodystrophy (MLD) in the US

EE547 The Societal Costs of Metachromatic Leukodystrophy (MLD) in the United States

EE125 Cost Consequences of Using Clevidipine in Acute Hypertension from the Perspective of a US Hospital

EE734 Cost Consequences of Using Clevidipine in Cardiac Surgery from the Perspective of a US Hospital

EE579 Cost Consequences of Using Clevidipine in Neurological Emergencies from the Perspective of a US Hospital

EE303 Cost-Utility Analysis of Roflumilast Cream for Plaque Psoriasis, Including Intertriginous, From the Canadian Societal Perspective

EE408 Direct Cost Analysis Associated with the Management of Patients with Metachromatic Leukodystrophy (MLD) across Nine European Countries

EE658 Cost-Consequence of Cladribine Tablets for the Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis (RRMS) in the UK

PMS57 Understanding the Impact of XLMTM on Parents and Caregivers in the US: An Analysis of Survey Results

PCN38 ECONOMIC ANALYSIS OF COLORECTAL CANCER SCREENING FROM MULTIPLE STAKEHOLDER PERSPECTIVES: KEY COMPONENTS TO IMPROVE PRACTICAL APPLICATIONS IN THE US

PRO10 USE OF SINGLE DOSE GENE-REPLACEMENT THERAPY FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY TYPE 1: A UNITED STATES PAYER BUDGET IMPACT ANALYSIS

ND2 COST-UTILITY ANALYSIS OF SINGLE DOSE GENE-REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY TYPE 1 COMPARED TO CHRONIC NUSINERSEN TREATMENT

PBI10 TYPE I SPINAL MUSCULAR ATROPHY PATIENTS TREATED WITH AVXS-101 HAVE LOWER USE OF VENTILATORY SUPPORT, HOSPITALIZATION, AND ASSOCIATED COSTS COMPARED TO THOSE TREATED WITH NUSINERSEN

PCN38 - Budget Impact of Metastatic Castrate-Resistant Prostate Cancer (CRPC) to German Payers

PIN32 - Use of Oritavancin for the Treatment of Skin and soft Tissue Infections: A Uk Hospital Budget Impact Analysis

PSS10 - A Us Hospital Economic Impact Model for Oritavancin In Absssi Patients With Risk of Mrsa Infections

Suchergebnisse filtern